title: Overactive bladder syndrome in older people.
abstract: The overactive bladder symptom complex (OAB) is the commonest cause of urinary incontinence in older people, and is usually due to underlying detrusor overactivity, and as such is a treatable condition. Older people are a heterogeneous group, which includes fit community-dwelling individuals and those with significant medical comorbidity; thus the requirements of care for this group are many and varied. The International Continence Society definition of the frail elderly, those aged >65 years with continence problems, who by virtue of comorbidity are house-bound or living in an institution, is clearly not applicable to all. However, many conditions begin to appear in later life and practitioners need to be aware of the need to manage these, and their treatment, when dealing with older people. Studies of medication for OAB have included the elderly and there is evidence of an equivalent benefit in younger people. The impact of treatment on the cognitively impaired and those receiving acetylcholinesterase inhibitors is discussed.
authors.affiliation: Department of Geriatric Medicine, University College London Hospitals, London, UK. a.wagg@ucl.ac.uk
authors.forename: Adrian S
authors.initials: AS
authors.lastname: Wagg
authors.forename: Linda
authors.initials: L
authors.lastname: Cardozo
authors.forename: Christopher
authors.initials: C
authors.lastname: Chapple
authors.forename: Dirk
authors.initials: D
authors.lastname: De Ridder
authors.forename: Con
authors.initials: C
authors.lastname: Kelleher
authors.forename: Michael
authors.initials: M
authors.lastname: Kirby
authors.forename: Ian
authors.initials: I
authors.lastname: Milsom
authors.forename: Mark
authors.initials: M
authors.lastname: Vierhout
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000150:complications*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology
chemical_list: D002800:Cholinesterase Inhibitors; D018727:Muscarinic Antagonists